Investor Relations

 

Clinical Laserthermia Systems (CLS) is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.

Financial calendar

 06/27/2025 Annual General Meeting  


08/22/2025 Interim Report 2/25 January – June  


11/14/2025 Interim Report 3/25 January – September  


02/20/2026 Year-end report 2025     

IR Contact

CEO Dan Mogren and CFO Håkan Rosqvist present the company’s Q1´25

Recorded 16 May 2025

Financial reports

Here you can view and download interim reports, full year reports and annual reports from CLS.

Press releases

Here you can find the regulatory notices published in accordance with the listing requirements of Nasdaq First North Stockholm where CLS’ shares are listed.

Investment case

CLS provides minimally invasive, cost-efficient solutions for soft tissue resection in patients with complex medical conditions. Using high-precision laser energy, guided by imaging and real-time control, our patented thermotherapy platform enables safe, effective thermal ablation.

Focused initially on neurosurgery, CLS is expanding into adjacent areas. CLS’s business focuses on in-house development and market approval of medical devices. Our regulatory-approved devices are then commercialized through strategic partners in the U.S. and Europe, with a vision to do so on a global scale.

 Our business model generates >60% gross margin with revenue from system sales and recurring revenue from procedure-based disposables, and supports rapid scaling across multiple therapeutic areas with minimal fixed costs.

Corporate governance

Good corporate governance is central to ensuring that a company is managed in the right way. At CLS, we are very meticulous about having good and clear corporate governance so that our investors feel confident in the company and in the decisions that are made.

The share

The CLS share was first listed on the Aktietorget stock exchange in 2009, but is since 2017 listed on Nasdaq First North Stockholm as CLS B.

Subscribe to news from CLS

Make sure you get all the exciting information about CLS’ progress.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US